Sign In
Buy SVRA
$5.25
+0 (+0%)
At Close: Jun 03, 2026
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
09:36am, Wednesday, 26'th Jun 2024
The latest trial study from Savara Inc SVRA met its primary endpoint.
Savara's rare lung disease drug meets main goal in late-stage study
06:41am, Wednesday, 26'th Jun 2024
Savara on Wednesday said its experimental drug, molgradex, met the main goal of a late-stage trial for treating a rare lung disease characterized by a feeling of breathlessness.
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pi
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conferen
3 Penny Stocks Poised for Major Upside Over the Next 5 Years
09:00am, Wednesday, 19'th Jun 2024
Though risky, there are certainly plenty of penny stocks to buy that have the potential to significantly boost portfolio returns. Of course, patience and a growth-friendly market are required for the
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
06:00am, Tuesday, 11'th Jun 2024
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.
Savara: The Binary Bet On Phase 3 Data
05:56am, Friday, 07'th Jun 2024
Savara is a biotech company focusing on the treatment of autoimmune pulmonary alveolar proteinosis. The company's valuation will be heavily impacted by the results of its upcoming IMPALA-2 trial for i
Savara to Present at the Jefferies Global Healthcare Conference
08:05am, Wednesday, 29'th May 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic
Savara Announces New Employment Inducement Grant
04:05pm, Thursday, 16'th May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new emp
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
04:05pm, Thursday, 09'th May 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first qua
Savara to Present at the Citizens JMP Life Sciences Conference
04:05pm, Tuesday, 07'th May 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstra
Savara Announces New Employment Inducement Grant
04:05pm, Friday, 22'nd Mar 2024
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new e
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
04:05pm, Thursday, 07'th Mar 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth qu
